Smaller groups await Bristol-Myers Squelgene fallout

As the dust settles on Bristol-Myers Squibb’s takeout of Celgene it is not just big pharma that is left wondering where it now stands. A slew of smaller companies that had tie-ups with Celgene also face a nervous wait to find out if Bristol sees promise in their projects or whether they are surplus to requirements.